We investigated efficacy of sorafenib therapy for advanced hepatocellular carcinoma (HCC) with Vp3/4 portal vein tumor thrombosis. According to modified RECIST, the therapeutic responses in Vp0/2 group (n=30) were 8 PR, 14 SD and 8 PD cases, and while those in Vp3/4 group (n=11) were 5 PR, 2 SD and 4 PD cases. The response rates and cumulative progression rates were not significantly different between two groups. The cumulative survival rates in Vp3/4 group were significantly lower than those in Vp0/2 group. The deteriorations of Child-Pugh scores in Vp3/4 group were significantly higher than those in Vp0/2 group. The possibility of the deterioration of liver function should be kept in mind during sorafenib therapy for advanced HCC with Vp3/4.
All Science Journal Classification (ASJC) codes